Rapid tests are most frequently used to diagnose infectious diseases, such as flu, malaria, HIV, and COVID 19, among others. Unlike most standard diagnostic tests, which are required to be sent to a lab for analysis, RDTs are performed and results are provided at the point-of-care.
The Global Rapid Diagnostic Tests (RDTs) Market is set to witness a CAGR of 4.5% from 2021 to 2026. High acceptance of point-of-care (POC) diagnostics, availability of advanced quick testing devices, rising prevalence of infectious & other chronic diseases, and growing geriatric population are some of the key factors boosting the global rapid diagnostic tests (RDTs) market.
High influence of COVID 19 fueled the demand for RDTs
The RDTs market has experienced a positive impact due to the COVID 19 pandemic. Even though the demand for RDTs specifically for the detection of SARS-CoV-2 during 2020 and 2021 increased exponentially, the pandemic showed a negative impact on the sales of RDTs for cancer screening, blood glucose, cardiac markers, and other infectious diseases, among others.
However, during the past two years, there has been a significant development in the global rapid diagnostic tests (RDTs) market; some of them are included below:
In October 2021, the NIH Rapid Acceleration of Diagnostics (RADx) initiative has awarded contracts totalling $77.7 million for the development and manufacturing of 12 new rapid diagnostic tests for SARS-CoV-2; offering high performance and low-cost home and POC tests
In September 2021, LumiraDx, a next-generation POC diagnostics company, launched its LumiraDx SARS-CoV-2 Ag Surveillance Test in the US market, specifically for use at schools and workplaces; which allows simultaneous testing of up to five samples on a small and portable instrument, costing $4 per sample and delivering digital results within 12 minutes
In July 2021, the Department of Defense (DOD), in coordination with the Department of Health and Human Services (HHS) has awarded a contract of $35.1 million to LightDeck Diagnostics, to scale-up the production capacity of LightDeckâ€™s SARS-CoV-2 Ultra-Rapid Antigen and COVID-19 Total Antibody Tests
In March 2021, FUJIFILM Corporation announced the launch of its antigen testing kit â€“ â€˜FUJIFILM COVID-19 Ag Testâ€™, for detecting SARS-CoV-2, which is developed by using highly-sensitive detection technology based on silver halide amplification
Explore Premium Report on Rapid Diagnostic Tests (RDTs) Market @ https://meditechinsights.com/rapid-diagnostic-tests-rdts-market/
Collaborations and acquisitions to increase acceptance and co-develop advanced solutions
The rapid diagnostic tests (RDTs) market has witnessed a number of acquisitions by market players to either enhance the adoption of these tests or to co-develop advanced diagnostic tests.
Some of the strategic initiatives that boost the adoption of RDTs are listed below:
In April 2022, bioMÃ©rieux entered into an agreement to acquire Specific Diagnostics, a developer of rapid antimicrobial susceptibility test (AST) system. Rapid AST provides fast and accurate AST results while reducing the global antimicrobial resistance (AMR) burden caused by antibiotic resistant pathogens
In February 2022, Sorrento Therapeutics, Inc. acquired a majority ownership of Zhengzhou Fortune Bioscience Co., Ltd. (FortuneBio), a diagnostic product manufacturer and Sorrentoâ€™s exclusive OEM manufacturer for COVISTIX. With enhanced sensitivity in detecting the Omicron variant, COVISTIX is a rapid antigen detection test for SARS-CoV-2 and its major variants of concern (VOCs)
In February 2021, Becton, Dickinson and Company collaborated with Scanwell Health, a provider of smartphone-enabled at-home medical tests, to develop an at-home rapid test for SARS-CoV-2 using Becton, Dickinson and Companyâ€™s antigen test and Scanwell Healthâ€™s mobile app
Competitive Landscape Analysis of Rapid Diagnostic Tests (RDTs) Market
The global rapid diagnostic tests (RDTs) market is marked by the presence of key players such as Abbott Laboratories (US), Bio-Rad Laboratories, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Becton, Dickinson and Company (US), and ACON Laboratories, Inc. (US), and others.
For More Detailed Insights, Contact Us @ https://meditechinsights.com/contact-us/
About Medi-Tech Insights
Medi-Tech Insights is a healthcare-focused business research & insights firm. Our clients include Fortune 500 companies, blue-chip investors & hyper-growth start-ups. We have completed 100+ projects in Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma Services.
Associate, Medi-Tech Insights
+32 498 86 80 79